UBS GLOBAL INDUSTRIALS & JIM VENA – CHIEF EXECUTIVE OFFICER JENNIFER HAMANN – CHIEF FINANCIAL OFFICER KENNY ROCKER – EVP MARKETING & SALES UNION PACIFIC CORPORATION TRANSPORTATION CONFERENCE UP-NS Merger: Path to Completion The Board of Directors of both Union Pacific and Norfolk Southern have unanimously approved the transaction STB application anticipated to be filed before the end of the year; analyst conference call to follow Transaction subject to obtaining Surface Transportation Board ("STB") approval ...

BANK OF AMERICA LEVERAGED FINANCE CONFERENCE DECEMBER 2025 © 2025 OPTION CARE HEALTH, INC. ALL RIGHTS RESERVED Disclaimers Forward-Looking Statements This presentation may contain "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "believe," "project," "estimate," "expect," "may," "should," "will" and similar references to fut ...

Oral Small Molecule Splicing Platform - PTC pioneered small molecule splicing therapies, with Evrysdi approved in over 100 countries and votoplam in development for Huntington's disease[21] - Small molecules enhance U1 interaction, increasing exon inclusion to generate distinct mRNA transcripts and modulate protein expression, exemplified by votoplam (PTC518)[22, 25, 29, 30] - PTC's PTSeek screening technology, leveraging learnings from SMA and HD programs, enables the discovery of novel sequence-selective 5' splice site enhancers for iExons[48, 96, 98] - PTC has discovered iExons throughout the entire transcriptome, covering a majority of genes, allowing for the targeting of splicing for novel small molecule enhancers[89, 90, 91] Splicing Platform Programs - MSH3 program targets nucleotide repeat disorders like Huntington's disease, with 30-50% MSH3 lowering stalling expansion in a human somatic expansion model[111, 129] - Spinocerebellar Ataxia 3 (SCA3) program aims to lower mutant ATXN3 protein production by inducing exon skipping[132, 141, 142] - Oncology program targets a key protein in cancer biology, with novel splicing modulators selectively inducing mRNA decay[147, 152] - Hemoglobinopathies program targets regulators of fetal hemoglobin (HbF) levels, with novel splicing modulators lowering a validated target of HbF induction[158, 163, 165] Inflammation & Ferroptosis Platform - PTC's inflammation and ferroptosis platform targets specialized enzyme hubs to regulate inflammation, energy production, and oxidative stress[179] - Parkinson's Disease program targets 15-LO to prevent ferroptosis-mediated cell death and alpha-synuclein aggregation[181, 183, 188] - PTC612, a highly selective NLRP3 inhibitor, demonstrates significant reduction in inflammatory cytokines and pathology across multiple preclinical models, with an IC50 of 099 nM in THP-1 cells[225, 227, 234]

Financial Performance - ITT reported Q3 2025 revenue of $999.1 million, a 12.9% increase compared to $885.2 million in Q3 2024[31] - Organic revenue growth for Q3 2025 was 6.1%[31] - Adjusted EPS for Q3 2025 was $1.78, a 21.1% increase compared to $1.47 in Q3 2024[43] - Free cash flow for Q3 2025 was $154.1 million, a 77% increase compared to $87.3 million in Q3 2024[17,53] - The company raised its full-year adjusted EPS guidance to a range of $6.62 to $6.68[16] Segment Performance (2024 Revenue) - Motion Technologies (MT) reported $1.4478 billion in revenue[26] - Industrial Process (IP) reported $1.361 billion in revenue[26] - Connect & Control Technologies (CCT) reported $825.1 million in revenue[26] Growth Metrics - The company achieved a 9% organic revenue CAGR and a 13% adjusted EPS CAGR over a 3-year period[11] - Average ROIC was 15%[11] - Total Shareholder Return (TSR) was +45%, outperforming the S&P 500 by +1,600 bps[11] Full Year 2024 vs 2021 (Organic) - Organic revenue grew by $805.3 million, a 30% increase[26] - Organic orders grew by $767.2 million, a 27% increase[28] Full Year 2025 Guidance - The company expects approximately $3.87 billion in revenue[53] - The company expects approximately $500 million in free cash flow[16,53]

Financial Performance - Q1 FY26 - Net sales decreased slightly by 0.4% to $7,840 million compared to $7,871 million in Q1 FY25 [14] - Adjusted EBITDA increased significantly by 24.6% to $167 million from $134 million in Q1 FY25 [14] - Adjusted EPS grew substantially by 250% to $0.56 from $0.16 in Q1 FY25 [14] - Free cash flow improved from $(159) million to $(54) million [14] Strategic Initiatives and Operational Efficiency - Network optimization actions reduced total net sales growth by approximately 3% [15, 24] - Net leverage ratio decreased to 3.2x, down 1.0x year-over-year [30] - Net debt decreased by $331 million year-over-year to $1,897 million [30] - Lean daily management was deployed at 34 out of 49 distribution centers by the end of the quarter [19] - New item setup time was reduced by 50% at the Chesterfield, NH Distribution Center [44] Fiscal Year 2026 Outlook - The company affirmed its fiscal 2026 outlook, including net sales of $31.6 - $32.0 billion and adjusted EBITDA of $630 - $700 million [36]

Financial Performance - Fiscal Year 2025 revenue was $27348 million, a decrease of 25% compared to $28058 million in Fiscal Year 2024[12] - Fiscal Year 2025 Adjusted EBITDA was $2574 million, down 271% from $3529 million in Fiscal Year 2024[12] - Q4 2025 revenue increased by 41% to $712 million compared to $6843 million in Q4 2024[12] - Q4 2025 Adjusted EBITDA decreased by 197% to $647 million compared to $805 million in Q4 2024[12] - Free cash flow for Fiscal Year 2025 was $58 million, a significant decrease of 964% compared to $1599 million in Fiscal Year 2024[12] - The company's net leverage ratio was 472x[6,30] Strategic Initiatives - The company is launching a multi-year strategic business transformation plan expected to generate annual cost savings of $75 million by the end of fiscal year 2026[6,37] - The transformation plan focuses on three pillars: Commercial Excellence, Operational Excellence, and Asset & Network Optimization[6,36] Fiscal Year 2026 Outlook - The company anticipates revenue of $27 billion[6] - The company anticipates Adjusted EBITDA in the range of $285 million to $315 million[6] - The company anticipates free cash flow in the range of $50 million to $60 million[6]

Acquisition Overview - PROG Holdings will acquire Purchasing Power for $420 million in cash[8, 34] - The acquisition is expected to contribute between $50 million and $60 million of Adjusted EBITDA in 2026[8] - The deal is anticipated to close in early 2026, pending regulatory approvals[34] Purchasing Power Highlights - Purchasing Power is a FinTech platform that allows consumers to buy goods and services over time via payroll deduction[12] - The company's 2026 revenue is projected to be between $680 million and $730 million[13, 34] - Approximately 90% of Purchasing Power's outstanding balance has payment terms of 12 months or less[14] - Purchasing Power has relationships with over 360 established employers[14, 19, 22, 28] - Purchasing Power has relationships with over 100 distribution partners[14, 19] - Purchasing Power reaches over 7 million eligible employees[14, 19, 22] - Purchasing Power has a 98% client revenue retention rate[14, 22] Strategic Benefits - The acquisition is expected to result in double-digit percentage EPS accretion in 2026[34] - PROG Holdings aims to maintain a net leverage ratio between 1.5x and 2.0x post-transaction[32, 34]

Company Strategy and Performance - Gibson Energy aims for a total shareholder return of over 100% by 2030[53] - The company targets a 7%+ average annual Infrastructure EBITDA per share growth[74, 107] - Gibson Energy's cost focus initiative drove operational excellence, recognizing $25 million in run-rate cost savings in 2025[31] - The company returned over $1.4 billion to shareholders since 2021[51, 87] Infrastructure and Operations - Gibson Energy has >25 mmbbl tankage capacity in North America[7] - The company achieved record throughput of 2.3 mmbbl/d across Canadian and U S terminals in 2025[30] - >95% of Q3 2025 Segment Profit came from Infrastructure[7] - >85% of Terminals Revenue is from Investment Grade customers[7] Financial Position and Outlook - The company targets capital investment of $100-150 million at 5–7x build multiples[33] - Gibson Energy expects to deploy up to $1 billion of growth capital over the next five years[66] - The company's dividend yield is 6.9%[7]

Financial Highlights - FY25 Pre-Tax Pre-Provision earnings increased by 9%, with adjusted earnings up by 15%[13] - FY25 revenues increased by 12%[15] - Q4 Return on equity was 11%, with adjusted return on equity at 12.5%, a year-over-year increase of 190 bps[15] - The company repurchased 10.8 million shares in FY25[15] - CET1 ratio stood at 13.2%[15] Segment Performance - Canadian Banking: Q4 pre-tax pre-provision earnings increased by 3% year-over-year[15] - International Banking: Q4 Net Interest Margin (NIM) increased by 12 bps year-over-year[15] - Global Wealth Management: FY25 net income increased by 18%, with operating leverage of 1.6% and net sales improved by $11.5 billion[15] - Global Banking and Markets: FY25 net income increased by 30%, with underwriting and advisory fees up by 35%[15] Capital Position and Risk Management - Q/Q CHANGE IN CET1 RATIO decreased by ~10 basis points Q/Q[25] - Total ACL ratio of 98 bps, up 2 bps Q/Q[57] - GILs are higher Q/Q by $354 million due primarily to formations mainly in Canadian Retail and Corporate portfolios, as well as the impact of foreign currency translation[68]

Q3 2025 Earnings Presentation BW LPG Kristian Sørensen and Samantha Xu 2 December 2025 Disclaimer and forward-looking statements NOT FOR RELEASE, PUBLICATION, DISTRIBUTION OR FORWARDING, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR IN TO ANY JURISDICTION IN WHICH THE SAME WOULD BE UNLAWFUL. BY ATTENDING THE MEETING WHERE THIS PRESENTATION IS MADE, OR BY READING THE PRESENTATION SLIDES, YOU ACKNOWLEDGE AND AGREE TO COMPLY WITH THE FOLLOWING RESTRICTIONS. This presentation has been produced by BW LPG Li ...